Media Release

• Leading IVD partner presents key diagnostic innovations at first-ever American Association for Clinical Chemistry (AACC) conference in Middle East
• Safe testing for women and heart health highlighted with special focus on exceptional support services to partners

Abu Dhabi, United Arab Emirates, 22 March 2018: Experts and specialists from across the region gathered to discuss the latest innovations in clinical laboratory medicine, in vitro diagnostics (IVD), and its impact on patient health and wellbeing, at the first ever Middle East edition of American Association for Clinical Chemistry’s (AACC) prestigious global conference held between March 22 and 24, in Abu Dhabi. The 3-day conference highlighted some of the latest advances in mobile health and molecular diagnostics among other technologies.

Leading biotechnology company Roche Diagnostics Middle East (RDME), presented its key innovations in diagnostics and testing at the conference while sharing best practices within the field. Its on-ground presence not only highlighted the high medical value of cardiac tests and their comprehensive women’s health testing portfolio across all life-stages, but also focused on their partnership program which provides further support to partners.

“Innovation in diagnostics is not just about bringing in new solutions and testing. It’s equally about knowing how to effectively use these innovations. As we continue to reaffirm our leadership in in-vitro diagnostics, we remain committed to increasing efficiency and productivity of lab testing which ultimately results in greater benefits to patients, considering 60% of clinical decision-making is based on in-vitro diagnostics test results”, said Harald Wolf, General Manager of Roche Diagnostics Middle East.

Clinical chemistry is a diagnostic method which tests for various components of blood and urine and enables healthcare professionals to overview significance of abnormal values. Roche Diagnostics has created integrated core lab concept - a fully connected laboratory in which every component is designed to work together as one - enabling within a single automated system, a vast array of testing across the healthcare continuum. With a focus to expand the core lab, the company is working to consolidate and further integrate a wider range of platforms covering other diagnostic disciplines such as molecular diagnostics and point-of-care testing.

Dr. Sameh El Sheikh, ALBORG Labs CEO and Medical Director of the AACC committee said, “The Middle East’s healthcare industry is on the technological fast-track, and with this comes the need for trusted operations of medical technology through qualified and trained personnel. The field of clinical chemistry links directly to patient safety through accurate testing and results, and it is only as effective as the hands that operate it”.

Attendees at the AACC Middle East edition have the opportunity to network with industry experts from the U.S., Europe and the Middle East to share knowledge on new breakthroughs in laboratory medicine.

 

About Roche Diagnostics Middle East (RDME):

RDME has taken the unprecedented move of being the first IVD Company to have a Management Centre and a logistics hub in the Middle East. RDME has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, RDME has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.

RDME offers a complete portfolio of services in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives.